What's Happening?
IDEXX Laboratories, a leader in pet healthcare innovation, has announced the integration of the renal biomarker SDMA into its Catalyst CLIPs, which are part of the most common point-of-care chemistry profiles.
This integration, set to be available in June for customers in the United States and Canada, aims to enhance the early detection of kidney function loss in pets. The SDMA test, recognized by the International Renal Interest Society, has been a critical tool in evaluating kidney health since its introduction in 2015. IDEXX has conducted approximately 119 million SDMA tests globally, highlighting its importance in veterinary diagnostics. The integration into Catalyst CLIPs allows veterinarians to identify kidney issues earlier and take action without disrupting existing workflows.
Why It's Important?
The integration of SDMA into routine diagnostic testing is significant as it allows for earlier detection of chronic kidney disease (CKD) in pets, a condition that is often unrecognized in its early stages. Early detection can lead to better management and treatment outcomes, potentially slowing disease progression and improving survival rates in affected animals. This development not only enhances the quality of care for pets but also supports veterinary practices by providing a more comprehensive diagnostic tool. For IDEXX, this move strengthens its market position and supports long-term growth by expanding the use of its diagnostic platforms.
What's Next?
With the integration of SDMA into Catalyst CLIPs, veterinarians will have access to more comprehensive diagnostic data during patient visits, enabling them to make more informed decisions about pet health. IDEXX is likely to continue expanding its diagnostic capabilities and integrating new biomarkers into its platforms. The company may also focus on increasing awareness and adoption of these advanced diagnostic tools among veterinary practices, potentially leading to further innovations in pet healthcare.
